Equities Analysts Issue Forecasts for JANX FY2029 Earnings

Key Points

• HC Wainwright has revised its earnings per share (EPS) estimate for Janux Therapeutics for FY2029 from $2.09 to $1.96, reflecting a more bearish outlook.
• Janux Therapeutics reported a quarterly EPS of ($0.55), which was below the consensus estimate of ($0.48), missing expectations by $0.07.
• The stock currently has an average rating of "Buy" with a consensus price target of $91.89, despite trading at $22.67, indicating substantial potential upside.

Janux Therapeutics, Inc. (NASDAQ:JANX - Free Report) - Stock analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Janux Therapeutics in a research note issued on Monday, August 11th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn $1.96 per share for the year, down from their previous forecast of $2.09. The consensus estimate for Janux Therapeutics' current full-year earnings is ($1.38) per share.

Separately, Raymond James Financial began coverage on Janux Therapeutics in a research note on Friday, July 11th. They issued an "outperform" rating and a $65.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $91.89.

Janux Therapeutics Stock Up 0.6%

NASDAQ:JANX traded up $0.14 during midday trading on Tuesday, hitting $25.11. The stock had a trading volume of 527,337 shares, compared to its average volume of 895,949. Janux Therapeutics has a one year low of $21.97 and a one year high of $71.71. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -13.95 and a beta of 2.86. The stock has a 50-day moving average of $24.61 and a 200 day moving average of $28.42.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.07).

Institutional Trading of Janux Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in JANX. LPL Financial LLC purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at $439,000. JPMorgan Chase & Co. lifted its holdings in shares of Janux Therapeutics by 941.8% in the 4th quarter. JPMorgan Chase & Co. now owns 191,603 shares of the company's stock valued at $10,258,000 after buying an additional 173,211 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Janux Therapeutics by 7.9% in the 4th quarter. Geode Capital Management LLC now owns 714,956 shares of the company's stock valued at $38,288,000 after buying an additional 52,362 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of Janux Therapeutics by 52.9% in the 4th quarter. Wells Fargo & Company MN now owns 13,251 shares of the company's stock valued at $709,000 after buying an additional 4,585 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in Janux Therapeutics by 77.7% in the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after purchasing an additional 442 shares during the period. Hedge funds and other institutional investors own 75.39% of the company's stock.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.